BCR-ABL fusion protein, a t(9;22) translocation product is indispensable for generation, maintenance and progression of chronic myeloid leukemia. RNA interference is an approach to silence gene at post-transcriptional level. We show that dsRNA targeted against the translocation region leads to more than 90% inhibition of BCR-ABL mRNA and protein expression levels using K562 as a model. Lack of BCR-ABL leads to cell cycle arrest in G1 phase as observed by decrease in cyclin D1 and increase in p21 and p27 cdk inhibitors mRNA. Apoptosis resistance imparted by BCR-ABL is lost in these cells in caspase-dependent or independent manner. Decrease in Bcl-X L is observed along with decrease in mitochondrial membrane integrity. Transient removal of BCR-ABL expression has a profound effect on proliferation and clonogenic capacity also confirmed by long-term silencing using lentiviral vectors. Interestingly, low level of BCR-ABL message leads to enhanced erythroid differentiation and reduced expression of megakaryocytic markers. Importantly, in six CML patient samples studied, silencing BCR-ABL in the lineage depleted enriched stem cell population leads to a decrease in colony-forming capacity. Thus, long-term silencing of BCR-ABL might prove to be a promising alternative approach in CML patients especially for those who do not respond to any other drug treatment.
Introduction
The Philadelphia (Ph) chromosome [t(9;22)-(q34;q11)] is the cytogenetic hallmark of human chronic myeloid leukemia. 1 This translocation results in the fusion of gene on chromosome 22 (BCR) to a portion of the ABL oncogene from chromosome 9. The fusion product BCR-ABL is important for CML disease maintenance and progression. CML is a stem cell disease. 2 During the initial chronic phase of CML, although BCR-ABL is expressed in multilineage compartments, the differentiation is normal; nevertheless, at a later blast crisis stage, blast with abnormal maturation increases. At cellular level, these leukemic blasts have now acquired apoptosis resistance, hyper-proliferation potential and minimal differentiation capacity. K562 cell line was derived from a CML blast crisis patient. Hence, it does reflect (to an extent) the abnormal molecular events at this stage of the disease.
In the presence of BCR-ABL, cells are unchecked at the G1-S phase transition, thereby imparting a growth advantage. 3 In particular, cyclin D1 and D2 are targeted by BCR-ABL. 4 Cdk inhibitors p21 and p27 are crucial checkpoints for the G1 to S phase transition. BCR-ABL inhibits p27 activity 5 and decreases p21 expression. 6 BCR-ABL as part of its transforming capacity imparts apoptosis resistance to the cells. Various signalling pathways have been shown to be involved in this process. 7 BCR-ABL has been shown to delay apoptosis upstream of procaspase-3 activation. 8 Further characterization of block in apoptosis reveals that BCR-ABL prevents mitochondrial perturbations. 9 Bcl-X L confers resistance against apoptosis by inhibiting the preapoptotic mitochondrial permeability transition and the activation of the executioner caspases. Various combinations of drug treatments have shown to be effective in decreasing these antiapoptotic proteins along with decrease in BCR-ABL expression and thus activating mitochondrial-induced apoptosis. [10] [11] [12] Caspase-independent necrosis-like programmed cell death was also induced by drugs that lead to inhibition of tyrosine kinase activity. 13 The p210 BCR-ABL protein has intrinsic tyrosine kinase activity, which has been implicated in the transforming capacity to BCR-ABL expressing cells. 14, 15 Thus, rational drug developments lead to the use of Imatinib that acts as potent inhibitor of BCR-ABL tyrosine kinase activity. Imatinib, though so far used to treat CML, acts as tyrosine kinase inhibitor for other translocations involving PDGFR, c-Kit and ARG. 16 However, transformation capacity of BCR-ABL has recently been shown to be independent of tyrosine kinase activity, 17 suggesting that blocking kinase activity is not sufficient to eliminate leukemogenic events introduced by BCR-ABL. Moreover, recent reports suggest that CML leukemic stem cells could become resistant to the kinase inhibitor, 18 again indicating multiple pathways involved in BCR-ABL-induced transformation independent of the tyrosine kinase activity. 19 An alternative explanation could be that Ph positive leukemic stem cells are quiescent and/or efflux Imatinib more effectively.
Thus, other methods are required to specifically study and target the leukemic properties of BCR-ABL. One strategy used overexpression of BCR-ABL in both human or mouse. Due to different source of cells targeted, there is inconsistency with regard to the downstream molecular events involved in BCR-ABL-induced leukemogenesis. The second approach is aimed at directly targeting BCR-ABL expression using antisense doublestranded DNA (dsDNA) is also undergoing further development.
Specific gene silencing has been shown to occur in mammals at post-transcriptional level by RNA interference. RNAi using small interfering RNAs (siRNA) of 22-23 base pair length targeted against the gene of interest results in degradation of complementary mRNA. As proof of principle, few groups have used siRNA to target BCR-ABL message as well. [20] [21] [22] [23] [24] Our data not only confirm these previous reports but also further elucidate the downstream events targeted by BCR-ABL.
We report here that silencing BCR-ABL protein is sufficient to cause cell death by caspase dependent and/or independent necrosis like programmed cell death. Interestingly, only a transient loss of BCR-ABL expression is sufficient to cause proliferation block at least for 2 weeks. The low level of BCR-ABL silencing in the long-term enables induction of erythroid differentiation and decrease in megakaryocytic markers in the K562 cell line model. Moreover, we show that the clonogenic potential is also severely affected not only in K562 but also in CML leukemic stem cell enriched fractions from six CML patients. Thus, the combination of lentiviral vectors and RNAi proves to be a useful tool to study the downstream pathways under the influence of BCR-ABL. Clinically, such an approach might prove to be promising, especially for patients in blast crisis who do not respond to any standard chemotherapeutic drugs regime and/or for Imatinib resistant patients.
Materials and methods

Cell culture
K562, 293T and HeLa cell lines (obtained from DSMZ) were cultured as described elsewhere. 
Primary cells
FACS internal staining
Cells were fixed, and stained with respective primary antibodies, followed by incubation with secondary antibody conjugated to FITC (fluorescein-5-isothiocyanate) or APC (allophycocyanin) (all from BD Biosciences, UK).
Cell cycle analysis by Hoechst staining
Cells were stained with 5 nmol/ml of Hoechst dye (Molecular Probes, OR, USA). Pulse processing was used to exclude unstained, apoptotic and clumped cells. Data were collected on LSR (Becton-Dickinson) and analysis was performed using FlowJo software.
Apoptosis detection assay
Cells were resuspended in Annexin V staining buffer as per the manufacturer's instruction (BD Pharmingen). Sub-G1 analysis was performed after fixing cells ethanol and counterstained with propidium iodide (PI). Mitochondrial membrane potential was measured using tetramethlyrhodamine ethyl ester (TMRE) and a DNA intercalating dye for live/dead analysis. TMRE fluorescence signal was detected using 575/26 BP filter excited by 488 nm laser.
Lineage depletion
CML mononuclear cells were labelled with lineage depletion cocktail antibody (Stem Cell Technologies). Negative selection was performed following the manufacturer's instructions. The lineage negative purity of 99% was assessed by using FITC conjugated Lin-1 antibody cocktail (BD Pharmingen).
Colony-forming assay
A total of 2000 cells from either K562 or CML lin neg cells plated in H3434 or H4435 GF þ , respectively (Stem Cell Technologies). Number of blast colonies was counted at day 10 for K562 and 15-20 for CML patients using inverted microscope. Each sample was plated in duplicates.
Proliferation assay
Mixture of XTT labelling reagent and PMS electron coupling reagent was prepared as per the manufacturer's instruction (Roche, Germany). Cells were plated in triplicates for each time point. Absorbance was measured at 490 nm.
Real time PCR
Total RNA at time points indicated was extracted using RNeasy kit (Qiagen, UK). cDNA synthesis was performed (using Qiagen Senscript reverse transcriptase). Real time PCR was performed using either Taq-man probes or SYBR-Green dye (Applied Biosystems, UK). For real time using SYBR-Green, dissociation curve was obtained for melting curve analysis to confirm PCR product specificity. Primers and probes used are shown in Supplement Table 1 along with their respective references. VIClabelled GAPDH primer/probe mix was purchased from Applied Biosystems.
Hemoglobin detection assay
Drabkin's reagent (Sigma D5941) was used for quantitative colorimetric determination of hemoglobin concentration as per manufacturer's instructions. Error bars represent s.e.m. from three experiments.
Lentivirus production and transduction
Self-inactivating pRRLsin.cPPT. PGK.EGFP.WPRE lentiviral vector was used along with pH1 shuttle vector (a kind gift from Dr Galy, Genethon, France). Transient transfection of pRRL (with/ without shB3A2) along with packaging vectors pMDG and pD8.91 were performed in 293T cells through PEI-mediated DNA delivery. 25 Lentivirus was concentrated by standard protocol described elsewhere.
MOI of 10 was used for infection of the vector alone or shB3A2 producing vector. K562 cells were incubated with required viral stock and polybrene 8 mg/ml in RPMI medium. Transduction was allowed to proceed for 48 h. Green fluorescence protein (GFP) positive cells were sorted to 99% purity using MoFlo (Dako-Cytomation, USA).
CML lin neg cells were transduced with the vectors mentioned above at MOI 20 in SFEM (Stem Cell Technologies) in the presence of 100 ng/ml of SCF and Flt3-L and 20 ng/ml of IL3 and IL6 purchased from Peprotech, UK. At 48 h posttransduction, cells were washed, and live cells were plated for CFU assay.
Results
Kinetics of BCR-ABL mRNA on silencing
K562 cells were electroporated with siRNA targeted against BCR-ABL (henceforth referred to as siB3A2). siControl that targets scrambled sequence was used as a control for nonspecific effects of siRNA transfection. Figure 1a shows the kinetics of BCR-ABL mRNA on treatment with siRNA. At mRNA level, by 72 h, about 50% of its expression is retained. Western blot analysis for BCR-ABL using antibodies directed against BCR shows a decrease in the p210 BCR-ABL protein in the K562 cells at 72 h post-electroporation ( Figure 1b ).
Enhanced apoptosis on BCR-ABL silencing
At blast crisis stage, BCR-ABL has been reported to increase apoptosis resistance. As shown in Figure 2a , specific treatment with siRNA against BCR-ABL leads to increased apoptosis. Figure 2a , middle panel shows an increase in the apoptotic and necrotic cell population only when treated with siB3A2. Another signature of apoptosis is DNA fragmentation that can be addressed by sub-G1 analysis. Since the experimental setup is using electroporation, certain amount of DNA damage is expected in control cells that underwent mock transfection (Figure 2b , left and right panels). Nevertheless, about two-fold increase in sub-G1 cell population was observed when BCR-ABL expression was specifically silenced (Figure 2b , middle panel). In live cells, TMRE accumulates in active mitochondria because of their high membrane potential. As apoptosis is induced, there is a decrease in mitochondrial membrane integrity and therefore its membrane potential. As shown in Figure 2c , the level of TMRE fluorescence decreases in cells treated with siB3A2, thus indicating decreased mitochondrial trans-membrane potential. Co-staining of the cells with DAPI confirmed a second cell population that showed decrease TMRE fluorescence and DAPI positivity suggestive of mitochondrialinduced apoptosis. At molecular level, Bcl-X L , the antiapoptotic member of Bcl family shows decrease in its mRNA and protein expression (Table 1 and Figure 2d ) whereas Bax, member of proapoptotic family shows increase in its mRNA expression, which peak 96 h post-transfection (data not shown). BCR-ABL expressing cells show a low level of Bcl-2 expression, suggesting that its survival function is not required. On removal of BCR-ABL message, Bcl-2 expression increases (Table 1 ). Other sign of apoptosis is procaspases cleavage and their activation. Caspase-7 and -9 are cleaved and activated in cells with siB3A2 ( Figure 2d ). Downstream events involved caspase-3 activation and PARP cleavage, thus suggesting increase in caspasemediated apoptosis (Figure 2d ) by multiple pathways in the absence of BCR-ABL.
BCR-ABL silencing reduces proliferation by cell arrest
We further wanted to address if BCR-ABL was also involved in hyper-proliferation of the leukemic blasts. In our transient silencing experiment using chemically synthesized siRNA, 50% of BCR-ABL mRNA level is restored within 72 h. Hence, only a Mock-transfected sample was assigned arbitrary value of 100%. All samples were normalized to internal control GAPDH. s.d. (7) values are given in parentheses. p21 real time PCR was carried out twice and p27 PCR was carried out once.
Short-and long-term silencing of BCR-ABL J Rangatia and D Bonnet transient change in cell proliferation was expected. Surprisingly, however, in siB3A2 treated cell population, silencing of BCR-ABL has a relatively long-term effect on their proliferation capacity (Figure 3a ). These cells are unable to actively divide for at least 2 weeks after transient silencing of BCR-ABL in comparison to the mock transfected or siControl transfected cells. One could argue that this effect could be due to the presence of apoptotic cells or that the surviving resting cells recover slowly after 5-7 days of transient BCR-ABL silencing. To address this question, 3 days after the siB3A2 treatment, cells were washed extensively to exclude dead cell or debris, recounted and replated for proliferation assay and similar results were observed (data not shown). These data strongly indicate that transient BCR-ABL silencing has a profound proliferative defect.
In order to determine the mechanisms behind this decrease in cell proliferation, we looked at the cell cycle profile of the cells using Hoechst 33342 DNA staining. Figure 3b indicates cell cycle arrest in G1 phase on treatment with siB3A2 in comparison to control samples (Figure 3b , left and right panels). There is a marked reduction in cells entering S and subsequent G2/M phase of the cell cycle on transient silencing of BCR-ABL expression (Figure 3b, middle panel) . Cyclin D is involved in G1 to S phase transition and its expression is often disrupted in various cancers. We therefore addressed the effect of BCR-ABL silencing on cyclin D. FACS analysis reveals a decrease in cyclin 
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D expression (Figure 3c ). Cyclin D comprises three isoforms: D1, D2 and D3. To further identify which cyclin D is involved in BCR-ABL-induced transformation, individual cyclin D member was analyzed at mRNA and protein level. At mRNA level, all three cyclin Ds showed decrease in expression similar to BCR-ABL expression pattern (data not shown); however, at protein level, only cyclin D1 showed a significant reduction in its expression (Figure 3d ). It is important to note that cyclin D protein level in these cells is very low. However, we do observe a significant logarithmic decrease in its expression in the siB3A2 treated cells. Cyclin-dependent kinase (cdk) inhibitors p21 and p27 are deregulated in the presence of BCR-ABL. In BCR-ABL transformed cells, the expression of these inhibitors is almost negligible, indicating the bypass in cell cycle checkpoint. On removal of BCR-ABL message, the mRNA level of these inhibitors is increased leading to a subsequent block in G1 cell cycle phase (Table 1) .
Prolonged BCR-ABL silencing by lentiviral vector affects similar downstream pathways
Based on results so far, we were convinced that downstream pathways affected during BCR-ABL induced leukemogenesis could be studied using RNA interference. However, the most important drawback of our approach to understand the role of BCR-ABL in disease maintenance/progression was the transient silencing effect. One could not address long-term effects of the lost of BCR-ABL expression in cells that switches off BCR-ABL expression only transiently. One way of extending the silencing effect was to develop a stable expression of the same inhibiting target sequence in form of short hairpin loop RNA (shRNA) by the human H1 promoter in a lentiviral vector backbone (referred to as shB3A2). As shown in Figure 4a , a reduction in BCR-ABL mRNA is observed in cells transduced with shB3A2 lentivirus. Apoptosis analysis either by Annexin V staining (Supplement Figure 1a) or by sub-G1 analysis (Supplement Figure 1b) clearly indicates increase in apoptosis on silencing BCR-ABL expression. Moreover, decrease in mitochondrial trans-membrane potential (Supplement Figure 1c) with subsequent activation of cleaved caspase 3, 7 and 9 was observed specifically in cells transduced to express shB3A2 (data not shown). Morphologically as well, cells expressing shB3A2 are similar to cells transiently expressing siB3A2 (data not shown) with distinct apoptosis signature.
In the lentiviral vector system, since GFP could be used as a marker for transduced cell population, these cells were sorted and followed to study long-term effect of BCR-ABL silencing. As shown in Figure 4c shB3A2) and colony size (data not shown), which can be due to decrease in proliferation or lack of self-renewal capacity, that is, induction of differentiation.
The long-term surviving cells shown in Figure 4c , right panel, shows an increase in Glycophorin A (Figure 4d, left panel) , an erythroid lineage marker. To confirm these findings, we repeated the transient BCR-ABL silencing experiments, and observed a similar increase in Glycophorin A (Figure 4e, left  panel) . Such an increase in Glycophorin A expression has been observed on treating K562 with Imatinib. We addressed the question if there was any dose-response relationship between Glycophorin A and BCR-ABL expression. To our surprise, Glycophorin A mRNA increase (Figure 4e, center panel) is reciprocal to the increase in level of BCR-ABL silencing. We further show that in the absence of BCR-ABL message, these cells can produce hemoglobin (Figure 4e, right panel) . K562 cells morphologically resemble erythro-megakaryocytic leukaemia cells. In vitro studies indicate that these cells can be induced to differentiate into either erythroid or megakaryocytic lineages. We therefore addressed the effect of silencing BCR-ABL on the megakaryocytic lineage potential of these cells. These cells show a corresponding decrease in CD61, a megakaryocytic marker (Figure 4d , right panel) along with decrease in early megakaryocytic marker vWF (data not shown). 
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BCR-ABL silencing leads to reduce colony-forming capacity in CML-enriched stem cell population CML lin neg population represents a small percent of the mononuclear cells and are CD34-enriched subpopulation with higher colony-forming cell frequency. 26 These cells like the normal lin neg are quiescent and difficult to target by Imatinib either due to very quiescent nature or high efflux of the inhibitor. 19 Using the BCR-ABL silencing lentiviral vectors, its expression is reduced to 40% of control in this stem cell population ( Figure 5a ). As observed with K562, we observed an increase in apoptosis in the shB3A2-transduced cells (Figure 5b , right panel). On plating these cells in complete cytokine medium, we observed that BCR-ABL silencing leads to a decrease in colony-forming capacity in comparison to cells transduced with vector backbone (Table 2 ) similar to what we observed with K562 cell line. Furthermore, we observed in most of the patient samples (seven out of nine tested), a decrease in granulocytic progenitors. Interestingly, in a CP patient an increase in erythroid progenitors was observed, which was further confirmed by the increase in Glycophorin A expression in the lin neg cells transduced with shB3A2 (data not shown).
Discussion
In this report, we have investigated the downstream pathways affected on silencing BCR-ABL expression. In recent years, preliminary reports indicate that silencing of BCR-ABL using RNA interference works consistently to reduce its expression. However, so far the molecular consequence of silencing BCR-ABL has not been studied systematically. Our studies indicate that silencing BCR-ABL leads to two effects depending on the level of silencing achieved. With the almost complete inhibition of BCR-ABL expression, cells start to undergo programmed cell death by either apoptosis or necrosis pathways. Earlier studies related to the effect of drug toxicity on BCR-ABL positive cells have indicated that increase in apoptosis is independent of its kinase activity. Our findings indicate that silencing BCR-ABL expression triggers both apoptosis and necrosis like programmed cell death with activation of executioner caspases and upregulation of proapoptotic members like Bax, Bcl-2 and downregulation of antiapoptotic Bcl-x L . These results indicate that resistance to apoptosis is related to the BCR-ABL expression and possibly its localization, interacting partners and/or its kinase activity. 17 The cells that do no trigger sufficient death stimulus due to low level of BCR-ABL silencing have a profound defect in proliferation. This is caused by cell cycle arrest at G1 phase of the cell cycle. In transformed cells that are actively undergoing cell proliferation, cyclin Ds' expression is not confined to G1 phase, but instead is expressed throughout the cell cycle. In the absence of BCR-ABL protein, cyclin D mRNA decreases, thus indicating that BCR-ABL regulates its expression at transcriptional level. However, at protein level, only the cyclin D1 expression decreases in cells lacking BCR-ABL, indicating that cyclin D1 is under post-translational regulation in the presence 27 thus suggesting an important interaction between BCR-ABL and cyclin D1 to maintain cells in continuous cell cycle and differentiation block. These data thus give an idea about the mechanisms of BCR-ABL transformation, that is, apoptosis resistance and hyperproliferation.
In patients presenting CML blast crisis, an increase in early stage hematopoietic maturation arrest is observed. At this stage, these blasts have acquired characteristics of hyper-proliferation and apoptosis resistance with minimal signs of maturation. K562 cell line derived from a patient in blast crisis truly represents this clinical manifestation. These cells show an erythro-megakaryotic lineage block and could be induced to differentiate into either lineage. Data presented here suggest that low but persistent BCR-ABL silencing despite being insufficient to induce apoptosis and/or complete cell cycle arrest could initiate differentiation/maturation of these cells. Indeed, we show that reduction of BCR-ABL expression leads to increase in erythroid lineage markers with subsequent decrease in megakaryocytic lineage markers. The fact that the reduction of BCR-ABL expression trigger K562 to differentiate indicates that the level of BCR-ABL is important in the physiopathology of disease progression. This is in agreement with the notion that in chronic phase the level of BCR-ABL transcript is lower than in acute phase, and thus the increase in the level of BCR-ABL transcript is predictive of disease progression. [28] [29] [30] Clinically, the BCR-ABL silencing approach might be of great relevance to convert acute or blast crisis phase back to chronic phase. As lentivirus vectors have the capacity to target non-dividing cells, it should be effective in targeting leukemic stem cells as shown here with nine CML lin neg enriched stem cell population. Bedi et al. 31 have shown that BCR-ABL mRNA transcript might be absent in early stem cell/progenitor population. BCR-ABL expression is seen once these cells show lineage commitment and thereby leads to leukemic expansion. With the strategy we propose, one could target these early stem/progenitor cell population when BCR-ABL expression is absent, and once it starts getting expressed, the BCR-ABL silencing shRNA would come into action. The advantage of this approach could be that there is minimal possibility of leukemic expansion and thus could help keep the disease under control. This could thus provide the patient with long-term disease free survival with minimal chances of relapse. Thus, long-term BCR-ABL silencing using lentiviral system might prove to be important therapeutically. We further suggest that a similar strategy could be exploited to target other translocations that are found to occurring as a primary event in pathogenesis of the leukemia.
